Verquv^®

Verquv is a preparation of Vericiguat which is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, Verquv® augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

Use in children and adolescents
Safety and effectiveness of vericiguat have not been established in pediatric patients.

Verquv is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Route of administration: Verquv should be taken in oral route with food. For patients who are unable to swallow whole tablets, Verquv® may be crushed and mixed with water immediately before administration or as directed by the physician. The recommended starting dose of Verquv is 2.5 mg once daily. Double the dose of Verquv approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

Pregnancy: Vericiguat may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy.

Lactation: There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from vericiguat, advise women not to breastfeed during treatment with vericiguat.

Special waming: Embryo-Fetal Toxicity

Vericiguat may cause fetal harm when administered to a pregnant woman. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential of the potential risk to a fetus, to use effective contraception during treatment with vericiguat and for at least one month after the final dose.

Most common side effects are hypotension and anemia.

Vericiguat is contraindicated in patients with known hypersensitivity to it or any other components of this product. It is also contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators and in pregnancy.

Drug interaction with medication: Vericiguat is not recommended in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. Concomitant use of vericiguat with PDE-5 inhibitors is not recommended because of the potential for hypotension.

Drug interaction with food and others: Not applicable.

Limited data are available with regard to overdosage in human patients treated with vericiguat. Vericiguat is generally well tolerated. In the event of an overdose, hypotension may result. Symptomatic treatment should be provided. It is unlikely to be removed by hemodialysis because of high protein binding.

No Data

No Data

Verquv 2.5 tablet: Each coated tablet contains Vericiguat INN 2.5 mg.
Verquv 5 tablet: Each coated tablet contains Vericiguat INN 5 mg.
Verquv 10 tablet: Each coated tablet contains Vericiguat INN 10 mg.

Storage
Store below 30°C in a dry place, protected from light. Keep away from the reach of children.

Packing
Verquv 2.5 tablet: Carton of 30 tablets in blister pack.
Verquv 5 tablet: Carton of 30 tablets in blister pack.
Verquv 10 tablet: Carton of 30 tablets in blister pack.